Objective: To analyze the failure pattern and clinical efficacy of elective nodal irradiation in patients with esophageal squamous cell carcinoma who received neoadjuvant chemoradiotherapy. Methods: We retrospectively analyzed 173 esophageal squamous cell carcinoma patients who received neoadjuvant chemoradiotherapy including elective nodal irradiation from 2002 to 2015. Failure pattern, survival and recurrence sites were analyzed. For patients with regional recurrences, the recurrence sites were analyzed in relation to an imaginary field of involved field irradiation. Results: After a median follow-up of 55.5 months, 58 patients (33.5%) developed recurrences. Among 22 patients with regional recurrences, infield failure occurred in 19 patients (86.4%) and outfield failure occurred in 3 patients (13.6%), of whom only 1 patient had an outfield failure without synchronous distant metastasis. Compared with the involved field irradiation field, 6 patients' failure sites (27.3%) were located in the involved field irradiation field and 13 patients' failure sites (59.1%) were out of the involved field irradiation field but within the elective nodal irradiation field. Conclusions: Since only a minority of patients had outfield regional recurrences, neoadjuvant chemoradiotherapy with elective nodal irradiation yields satisfactory infield control. More than half of the regional recurrences occurred within the elective nodal irradiation field but out of the involved
Introduction
As the sixth leading cause of cancer death in the world, esophageal cancer (EC) is a common and aggressive malignancy (1, 2) . When compared with surgery alone, it has been well demonstrated that neoadjuvant chemoradiotherapy (CRT) followed by surgery could significantly improve locoregional control and long-term overall survival (OS) (3) (4) (5) . Therefore, trimodality therapy has become the standard of care for locally advanced EC in both squamous cell carcinoma (SCC) and adenocarcinoma.
Although radiotherapy plays an important role in the treatment of EC, there is still no consensus on the accurate definition of the clinical target volume (CTV). The National Comprehensive Cancer Network guidelines recommend that CTV should include the areas at risk for microscopic disease as well as elective nodal regions, depending on the location of the primary tumor in the esophagus (6) . When considering the benefit of better locoregional control, the choice of elective nodal irradiation (ENI) seems rational and logical in theory. Nevertheless, severe radiation-related toxicities including grade 3 or higher radiation pneumonitis, myocardial damage and esophagitis could accompany ENI (7) . Therefore, a series of studies have investigated the efficacy of involved field irradiation (IFI) in EC patients treated with definitive CRT in recent years (8) (9) (10) . The results demonstrated that IFI is a feasible treatment option for inoperable patients to decrease the risk of radiation-related toxicity without sacrificing survival outcomes, especially for elderly patients. However, given the differences in recurrence patterns between neoadjuvant CRT and definitive CRT, it is unjustified to generalize the outcomes to another treatment modality (11, 12) .
There is a paucity of data regarding comparative outcomes between ENI and IFI in EC patients treated with neoadjuvant CRT. Therefore, the role of ENI in this subsetting is still unclear. The aim of this study was to analyze the failure pattern and clinical efficacy of ENI in esophageal squamous cell carcinoma (ESCC) patients undergoing neoadjuvant CRT followed by esophagectomy and to evaluate whether ENI is necessary in these patients.
Materials and methods

Patients
All patients with locally advanced ESCC (T1N+M0 or T2-4aN0-3M0) who underwent neoadjuvant CRT followed by esophagectomy from January 2002 to May 2015 at our institution were retrospectively reviewed. Patients were included according to the following criteria: (i) histologically confirmed thoracic ESCC without non-regional lymph nodes or distant metastasis: (ii) Eastern Cooperation Oncology Group Performance status score ≤ 2; (iii) radiotherapy technique was three-dimensional conformal radiotherapy (3DCRT) or intensitymodulated radiotherapy (IMRT); (iv) no history of previous or concomitant malignancy and (v) surgery was performed using Ivor Lewis esophagectomy with two-field lymphadenectomy. Patients with incomplete resection and those who died before hospital discharge were excluded. The institutional review board approved this study and waived the requirement for written informed consent due to its retrospective nature.
Staging procedure
Staging was determined according to the seventh American Joint Committee on Cancer staging system (13) . Pretreatment workup included complete history, physical examination, routine blood and biochemical test, barium swallow test, pulmonary function test, contrast-enhanced computed tomography (CT) of neck/chest/abdomen, esophagogastroduodenoscopy (EGD) with endoscopic ultrasound and biopsies, and/or positron emission tomography (PET).
Treatment
Before the initiation of treatment, all patients were evaluated by a multidisciplinary team according to institutional practice guidelines. As described previously, all patients received concurrent platinumbased chemotherapy regimens during radiotherapy (14) . External beam radiation was delivered by using 3DCRT or IMRT technique. The typical prescribed dose was 40 Gy in 20 fractions with 5 days per week. The gross tumor volume (GTV) was defined as the visible esophageal tumor (GTV-T) and any involved regional lymph nodes (GTV-LN) based on all available imaging studies. CTV was defined as the GTV-T plus a 3.0 cm longitudinal margin and a 0.5-1.0 cm circumferential margin, GTV-LN plus a 0.5-1.0 cm radial margin as well as elective nodal regions. Regardless of the site of primary tumor, the periesophageal and mediastinal nodes were included as regional lymph nodes in elective irradiated field, whereas supraclavicular lymph nodes were not included. For tumors located at the lower third of the esophagus or near the esophagogastric junction, ENI also included perigastric and celiac lymph nodes. The planning target volume (PTV) was defined as the CTV by plus a 0.8 cm margin in all directions.
Four to six weeks after the completion of neoadjuvant CRT, all patients underwent preoperative restaging, including barium swallow test, enhanced thoracoabdominal CT, EGD with biopsies. Esophagectomy was performed using transthoracic technique (Ivor Lewis) with two-field lymphadenectomy by the operating team. Pathologic complete response (pCR) was defined as no vital tumor cells either in the esophagus or in the resected lymph nodes.
Follow-up and recurrences
Follow-up after surgery took place every 3 months for the first 2 years, every 6 months for the next 3 years and annually thereafter. At each routine follow-up physical examination, blood tests, barium swallow test, CT and periodic EGDs were performed. The data were last updated in October 2017.
Recurrence time was referred to the time of the first recurrence. Histological and/or explicit radiological proof was required before diagnosis of recurrence. Recurrences were classified as local, regional and distant recurrences. Local recurrences were defined as recurrences within the esophagus, and regional recurrences were defined as recurrences within regional lymph nodes. Distant recurrences were defined as non-regional lymph node recurrences (supraclavicular or para-aortic nodes) and any distant organ metastases.
For patients with regional recurrences, the precise localization of recurrences were determined and correlated to the radiation field volumes. Infield failure was defined when recurrences occurred within the PTV, whereas outfield failure was defined when recurrences occurred outside the PTV. In addition, the sites of regional recurrences were further analyzed in relation to an imaginary field of IFI, which is consistent with consensus volumes of radiation therapy oncology group. For IFI, CTV was defined as the GTV-T plus a 3.0 cm longitudinal margin and a 0.5-1.0 cm circumferential margin, and GTV-LN plus a 0.5-1.0 cm margin in all directions.
Statistical analysis
Statistical analyses were performed using SPSS version 21.0 (SPSS Inc., Chicago, IL, USA) and P < 0.05 was considered statistically significant. OS was calculated from the date of surgery until death or last follow-up. Recurrence-free survival (RFS) was calculated from the date of surgery until the first event of recurrence. Locoregional recurrencefree survival (LRRFS) and distant metastasis-free survival (DMFS) were defined from the date of surgery to the time of first locoregional or distant metastasis, respectively. Kaplan-Meier methodology was used to evaluate survival probabilities and log-rank test was used to compare survival differences on univariate analysis. On multivariate analysis, Cox proportional hazards model was employed for the analysis of prognostic factors. Covariates with P < 0.15 in the univariate analysis were entered into the multivariate analysis.
Results
Patient characteristics
A total of 173 patients who completed neoadjuvant CRT and curative esophagectomy were eligible for the analysis. Patient characteristics and treatment details are shown in Table 1 . The median age of this cohort was 55 years (range, 42-73 years) and the male-tofemale ratio was 5.2:1. Of them, 81.5% of patients were treated with 3DCRT and 18.5% were treated with IMRT. The majority of patients (84.4%) received the standard radiation dose of 40 Gy and 27 patients (15.6%) received relatively higher radiation dose of >40 Gy (range, 41.4-50.4 Gy). After histopathological examination, 78 patients (45.1%) achieved a pCR.
Follow-up and recurrences
The median follow-up intervals for the whole cohort and for the 112 survivors were 38.5 months (range, 3.3-180.7 months) and 55.5 months (range, 7.7-180.7 months), respectively. At the time of this analysis, a total of 58 patients (33.5%) developed recurrences and the details of the recurrence sites are summarized in Table 2 . Six patients, 22 patients and 42 patients (including non-regional node failure in 25 and distant organ metastases in 23) developed local, regional and distant recurrences, respectively (Fig. 1) . A total of 75.9% of the relapses occurred within 2 years of follow-up. The median time to local failure, regional failure and distant metastasis 
Correlation between recurrence sites and radiation field
Among the 22 patients with regional recurrences infield failure occurred in 19 patients (86.4%) and outfield failure occurred in 3 patients (13.6%), of whom only 1 patient had an outfield failure without synchronous distant failure. When these failure sites were compared with the imaginary field of IFI, 6 patients' failure sites (27.3%) located in the IFI field and 13 patients' failure (59.1%) were out of the IFI field but within the ENI field. For the 14 patients who had regional recurrence without any evidence of distant metastases, 28.6% (4/14) of the failure sites were located within the IFI field, 64.3% (9/14) within the ENI field and only 7.1% (1/14) failed in gastric lymph nodes, which was zoned outside the ENI field. Regarding non-regional nodal recurrences, supraclavicular area was the most common failure site followed by para-aortic area ( Table 2 ). Nineteen patients (76.0%) with non-regional failure developed supraclavicular recurrences (one patient had synchronous para-aortic failure) and the other six patients (24.0%) failed in paraaortic area alone. The primary tumor locations in esophagus for patients with supraclavicular failure were as follows: upper 5.3% (1/19), middle 84.2% (16/19) and distal 10.5% (2/19), respectively. Among the 14 patients who had supraclavicular recurrences without evidence of any other site failure, 92.9% (13/14) of primary lesions were located in the middle esophagus and the remaining 7.1% (1/14) were located in the distal esophagus. 
Prognostic factors for locoregional recurrence
As shown in Table 3 , age, concurrent chemotherapy regimen, pathologic N stage and pathologic response significantly affected LRRFS on univariate analysis. On multivariate analysis, only age [hazard ratio (HR), 0.224; P = 0.002] and pathologic response (HR, 3.192; P = 0.045) were identified to be independent prognostic factors for LRRFS.
Discussion
Previous literature has demonstrated that the locoregional failure rate is approximately 12-17% in EC patients treated with neoadjuvant CRT followed by surgery (11, (15) (16) (17) , which is confirmed by our study. Based on a relatively large cohort of patients, the current study identified that neoadjuvant CRT with ENI could yield satisfactory infield control in patients with ESCC, as only a minority of patients had outfield regional recurrences. More importantly, more than half of the regional recurrences occurred within the ENI field but out of the IFI field, suggesting that ENI may be necessary in these patients.
The delineation of CTV is critical to improve therapeutic effect and decrease radiation-related toxicity. Huang et al. analyzed clinicopathologic factors of 1077 thoracic ESCC related to lymph node metastasis and supported that selective regional irradiation including correlated lymphatic drainage regions should be performed (18) . Onozawa et al. reported that ENI was effective for preventing regional nodal failure, especially for patients achieving clinical complete response after definitive CRT (19) . However, in the study reported by Zhao et al. and Yamashita et al., IFI did not demonstrate significantly different OS and local control rates but significantly decreased esophageal and lung toxicities when compared with ENI (9,10). On the basis of these findings, IFI has been widely accepted as definitive CRT in EC. On the other hand, the necessity of ENI in neoadjuvant CRT for EC remains controversial due to insufficient published clinical data. Hsu et al. retrospectively compared the efficacy between ENI and IFI in patients with ESCC undergoing neoadjuvant CRT, including 73 patients with ENI and 45 patients with IFI (20) . The results indicated that ENI reduced the M1a failure but was not associated with improved pCR rate or survival outcomes. On the contrary, Kim et al. found that nearly half of the locoregional relapses were out of the IFI field but within the ENI field, supporting the utility of ENI in neoadjuvant CRT for EC (21) . In our study, nearly 90% of regional failure sites were located within the ENI field, indicating that the definition of CTV was sufficient and justified. The further analysis revealed that 59.1% of regional recurrences were situated in the ENI field but out of the IFI field, similar to the results reported by Kim et al. (21) . Moreover, for patients who had regional recurrences without evidence of distant metastasis, the recurrence rate in the ENI field, but out of the IFI field, was even higher (64.3%). Therefore, it is necessary to prospectively evaluate the role of ENI in EC patients treated with neoadjuvant CRT.
How to further improve locoregional control in EC patients who received neoadjuvant CRT is a critical question. Considering that higher radiation dose might increase the risk of surgical complications, we routinely utilize the radiation dose of 40-45 Gy at our institution, which is lower than the North American standards of 50.4 Gy. Whether higher radiation dose could improve locoregional control and the ideal radiation dose in the neoadjuvant setting is unclear. In a recent population-based study reported by Madden et al., 50.4 Gy was associated with higher pCR rate for esophageal adenocarcinoma but not for SCC when compared to 41.4 Gy (22) . Moreover, no differences in OS were observed between dose cohorts. Since only 27 patients received higher dose (>40 Gy) in our study, the limited number of patients did not permit us to reach a conclusion in this regard. On the other hand, radiotherapy modalities may also play a role in locoregional control. In our study, only 1 out of 32 patients who received IMRT vs. 14 out of 141 patients who received 3DCRT had ENI failure, suggesting that advanced radiation technology may increase locoregional control. Lin et al. reported that 3DCRT patients had a significantly greater risk of locoregional recurrence (P = 0.038) and worse OS (P < 0.001) compared with IMRT (23). In addition, based on the physical and biological superiority, proton therapy has the potential to achieve further clinical improvement. In the study reported by Xi et al., proton therapy was associated with improved OS and LRRFS compared with IMRT, especially in EC patients with locally advanced disease who received definitive CRT (5-year LRRFS: 62.6% vs. 43.4%, P = 0.051) (24) . Therefore, the dosimetric advantages of advanced radiotherapy modalities might translate into clinical benefit.
In order to avoid anastomotic leaks after trimodality therapy supraclavicular lymph nodes were not included in the CTV at our institution. A total of 11.0% of the included patients had supraclavicular recurrences in our study and nearly 90% of the corresponding primary tumors were located in the upper or middle esophagus. The supraclavicular recurrence rate (4.2%) reported in the CROSS trial of neoadjuvant CRT group was much lower than that found in our study (15) . Differences in histology and target volumes may explain this observation. In the study reported by Hsu et al., ENI included supraclavicular lymph nodes if the primary tumor was located in the upper or middle esophagus (20) . The results indicated that more patients in the IFI group had supraclavicular failure than in the ENI group, with 3-year rates of 11% vs. 3%. Therefore, prophylactic supraclavicular irradiation should be considered for patients with upper or middle ESCC. However, it should be noted that supraclavicular irradiation may increase the risk of anastomotic leaks for patients undergoing Mckeown esophagectomy, which is often performed for upper or middle EC. As reported by Juloori et al., esophagogastric anastomosis placed within the preoperative radiation field was a strong predictor for anastomotic leaks (25) . Therefore, if prophylactic supraclavicular irradiation is conducted, the dose exposing to the cervical esophagus should be as low as possible and proper anastomotic placement after CRT should be evaluated carefully.
This study has several limitations. First, it is a retrospective study from a single institution. Second, not all patients had PET staging at baseline and not all recurrences were diagnosed with pathological proof, which may influence the accuracy of staging and recurrence information. Finally, treatment modalities including chemotherapy regimens and radiotherapy techniques were not identical in this cohort. Therefore, multi-institutional validation with larger patient cohort and complete baseline imaging tools is warranted to confirm our results.
Conclusions
Since only a minority of patients had outfield regional recurrences, neoadjuvant CRT with ENI yields satisfactory infield control in ESCC. Moreover, more than half of the regional recurrences occurred within the ENI field but out of the IFI field. Prospective evaluation of whether ENI could lead to an improved survival outcome is necessary.
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